^
Association details:
| Biomarker: | ER expression |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug Class: | Immunotherapy + Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Immunohistochemical expression of ER and p53 as predictive biomarkers of immunotherapy in endometrial cancer.
Published date:
05/25/2023
Excerpt:
ER positivity was associated with significant PFS benefit in both the ICI monotherapy group (11.9 vs. 0.63 months, p=0.061) and the group that received ICI/TKI combination (11.3 vs. 1.75 months, p=0.001)….ER-positivity remained an independent predictive factor favoring PFS in the Multivariate Cox regression analysis when adjusting for immunotherapy type, histology, and previous lines of therapy (HR=0.216, p=0.013)....ER expression proved to be an independent prognostic factor regarding PFS in our cohort of patients.
DOI:
10.1200/JCO.2023.41.16_suppl.e17626
